Incyte (INCY) Other Non-Current Assets (2010 - 2026)
Incyte (INCY) posted Other Non-Current Assets of $1.8 million for Q1 2026, down 0.86% on a QoQ basis from $1.9 million in Q4 2025, and down 93.91% year-over-year from $30.2 million in Q1 2025.
Incyte (INCY) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Incyte's Other Non-Current Assets history runs 16 years deep, the most recent figure standing at $1.8 million for Q1 2026.
- Quarterly Other Non-Current Assets fell 93.91% year-over-year to $1.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 million (down 93.91% YoY) and the FY2025 annual result came in at $1.9 million, up 14.18% from the prior year.
- Other Non-Current Assets was $1.8 million for Q1 2026 at Incyte, down from $1.9 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $81.0 million in Q3 2023 and bottomed at $1.6 million in Q4 2024.
- A 5-year average of $22.7 million and a median of $23.0 million in 2022 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2023 — Other Non-Current Assets soared 2968.73% — and 2024, when it plunged 97.85%.
- Incyte's Other Non-Current Assets stood at $1.7 million in 2022, then surged by 2968.73% to $52.1 million in 2023, then tumbled by 96.89% to $1.6 million in 2024, then rose by 14.18% to $1.9 million in 2025, then declined by 0.86% to $1.8 million in 2026.
- Business Quant data shows INCY's Other Non-Current Assets at $1.8 million in Q1 2026, $1.9 million in Q4 2025, and $32.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.02 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 104.24 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.26 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.13 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 124.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 14.48 Mn |
| 10 | Incyte | 23.33 Bn | 19.32 Bn | 1.17 Bn | 1.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.84 Mn |
| Dec 31, 2025 | 1.85 Mn |
| Sep 30, 2025 | 32.30 Mn |
| Jun 30, 2025 | 32.55 Mn |
| Mar 31, 2025 | 30.15 Mn |
| Dec 31, 2024 | 1.62 Mn |
| Sep 30, 2024 | 1.74 Mn |
| Jun 30, 2024 | 1.63 Mn |
| Mar 31, 2024 | 47.40 Mn |
| Dec 31, 2023 | 52.11 Mn |
| Sep 30, 2023 | 80.96 Mn |
| Jun 30, 2023 | 1.72 Mn |
| Mar 31, 2023 | 20.72 Mn |
| Dec 31, 2022 | 1.70 Mn |
| Sep 30, 2022 | 23.67 Mn |
| Jun 30, 2022 | 23.01 Mn |
| Mar 31, 2022 | 31.42 Mn |
| Dec 31, 2021 | 1.72 Mn |
| Sep 30, 2021 | 24.79 Mn |
| Jun 30, 2021 | 20.45 Mn |